Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC

NCT07038460 is registered in ClinicalTrials.gov with Wen-zhao ZHONG as lead sponsor.

NCT NCT07038460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07038460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
Lead sponsor
Wen-zhao ZHONG
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 31, 2025
Completion date
December 31, 2029
Enrollment
134 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

resectable non-small cell lung cancer